Viyash Scientific (VIYASH) Share News & Alerts

Viyash Scientific rises after subsidiary inks Rs 188-crore deal to acquire Italy's BioForLife

▲ Bullish +4.63%

The 100% strategic acquisition of Milan-based BioForLife for ₹188 crore provides Viyash Scientific direct entry into Europe's high-margin companion animal health market, utilizing a platform that already serves over 80% of Italian veterinary clinics. This inorganic expansion successfully shifts the mix away from low-margin human generics and creates a strong front-end for pipeline launches. Given the size of the deal relative to its financial footprint, this catalyst is expected to fuel a structural, bullish swing and positional re-rating over the medium term.